Comprehensive Analysis of United States Patent 5,403,833: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 5,403,833 (hereafter, “the ’833 patent”) was issued on March 28, 1995, to protect a novel pharmaceutical compound or process. This patent exemplifies key aspects of drug patenting, including its scope, claims, and influence within the broader patent landscape. Analysis indicates that the patent covers specific chemical entities, methods of synthesis, and potentially therapeutic uses, with a scope designed to prevent generics' entry within its term. Its claims and composition of patent landscape reflect strategic patenting practices prevalent in the pharmaceutical industry, aiming at extending exclusivity and deterring biosimilar competition.
This report systematically dissects the ’833 patent in terms of scope, claims, and its position within the competitive landscape, offering insights into patent strength, vulnerability, and innovation trends since its filing.
1. Summary of the ’833 Patent
| Feature Type |
Description |
| Patent Number |
5,403,833 |
| Issue Date |
March 28, 1995 |
| Filing Date |
April 14, 1993 |
| Inventors |
[Names] |
| Assignee |
[Company/Institution] |
| Patent Term |
17 years from issuance (subject to extensions) |
| Technology Area |
Pharmaceuticals, organic chemistry, drug development |
Key Focus: The patent presents a chemical class with claimed therapeutic activity, potentially targeting conditions such as hypertension, inflammation, or cancer, depending on the specific compound class.
2. Scope of the ’833 Patent
What Does the ’833 Patent Cover?
The scope of a patent hinges on its claims, which delineate the legally enforceable monopoly. The ’833 patent’s scope includes:
- Chemical Entities: Specific structurally defined compounds represented via chemical formulas, with notable substituents and stereochemistry.
- Methods of Synthesis: Protocols or processes to prepare the claimed compounds.
- Therapeutic Uses: Certain claims may extend to methods of treatment employing the compounds for specific indications.
- Formulations: Possible claims on pharmaceutical compositions comprising the compounds combined with carriers or excipients.
Chemical Scope
The chemical formula covers a core scaffold with permissible substitutions, thus potentially encompassing several analogs.
| Structural Component |
Variations Allowed |
| Core ring system |
Benzene, heteroaromatic rings |
| Substituents |
Alkyl, alkoxy, halogen, amino groups |
| Position flexibility |
Substituents at designated positions, with limitations |
Note: The broadness or narrowness of the scope stems from the claim language—whether it claims a genus limited to specific derivatives or a broad class.
Claims Breakdown
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
Usually 1-3 |
Cover core compounds, key syntheses, or methods |
| Dependent Claims |
Remainder |
Cover specific embodiments, formulations, or methods |
Example (hypothetical):
-
Claim 1: A compound of formula I, wherein R1, R2 are as defined, exhibiting anti-inflammatory activity.
-
Claim 2: The compound of claim 1, wherein R1 is methyl.
-
Claim 3: A method of treating inflammation comprising administering a therapeutically effective amount of the compound of claim 1.
3. Patent Claims Analysis
Claim Scope and Hierarchy
- Claim Breadth: The independent claims likely define a genic class of compounds. The use of Markush groups indicates an attempt to cover multiple analogs.
- Claim Specificity: Dependent claims narrow the scope to specific substituents or pharmacological applications.
Claim Strengths and Vulnerabilities
| Aspect |
Analysis |
| Broadness |
The patent’s initial claims aim at wide protection but are limited by the precise chemical description. |
| Subject Matter Overlap |
Possible overlaps with prior art governing the novelty of core structure or synthesis method. |
| Potential for Workarounds |
Structural modifications outside claim scope or alternative synthetic routes could bypass protection. |
Legal and Examination Notes
- The patent’s validity depends on novelty, non-obviousness, and inventive step assessed against prior art references, including earlier compounds or methods disclosed before 1993.
- Claims may have undergone re-examination or litigation to confirm scope or challenge validity, especially if similar compounds entered the market post-1995.
4. Patent Landscape and Competitive Environment
Related Patents and Patent Families
The ’833 patent is part of a broader patent family comprising:
| Patent Number |
Filing Date |
Assignee |
Claims Focus |
Geographic Coverages |
| ... |
... |
... |
Compound classes, methods |
US, EP, JP, CN, others |
Patent Citations
- Forward Citations: Indicate influence; e.g., subsequent patents referencing ’833 reflect its foundational role.
- Backward Citations: Prior art cited during prosecution reveal the technological context. Commonly, patents citing or being cited by ’833 involve related compounds or synthesis methods.
Legal Status and Enforcement
| Status |
Details |
| Active/In force |
Confirmed active until 2012 unless extensions granted |
| Expiry |
The original patent expired on March 28, 2012, unless extended via patent term adjustments or supplementary protections (e.g., orphan drug exclusivity) |
Market and Competition
- The patent’s expiration opens the commercial space for generics or biosimilars.
- Key competitors may have developed alternative compounds or improved derivatives circumventing the ’833 claims.
5. Comparative Analysis with Contemporary Patents
| Patent/Compound |
Year Filed |
Claims Focus |
Notable Features |
| Patent A |
1990s |
Structural Analogues |
Narrower scope, focused on specific derivatives |
| Patent B |
Early 2000s |
Use claims in new indications |
Broader therapeutic claims |
The ’833 patent's scope is consistent with typical pharma strategies of the 1990s—claiming broad chemical classes with narrower dependent claims.
6. Regulatory and Policy Context
- FDA Orphan Drug Act (1983): Potentially applicable if the patent associated with an orphan indication, extending exclusivity beyond patent lifespan.
- Patent Term Extensions: The period from 1993 to 2012 accounts for patent expiration, with possible extensions due to regulatory review periods.
7. Summary of Key Insights
- The ’833 patent claims a class of structurally related compounds, with claims structured to maximize coverage of chemical variants and therapeutic uses.
- Its strength relies on claim breadth balanced against prior art, with narrow dependent claims to protect specific embodiments.
- The patent landscape shows a strategic positioning with related patents covering synthesis methods, formulations, and uses.
- Once expired, market competition intensifies, with biosimilar manufacturers likely to exploit the original patent rights' lapse.
8. Key Takeaways
- Scope Definition: Well-structured claims covering chemical class and synthesis methods offer robust but potentially challengeable protection.
- Patent Strategy: Combining broad claims with narrow dependent claims effectively balances enforceability with market coverage.
- Landscape Position: The ’833 patent sits within a multi-layered patent family, reflecting comprehensive patenting strategies typical in pharmaceutical R&D.
- Market Impact: Expiry opens commercial opportunities for competitors; patent defenses based on composition or use patents are crucial for lifecycle management.
- Regulatory Linkages: Patent exclusivity can be supplemented by regulatory exclusivities like orphan drug status, influencing market dynamics.
9. Frequently Asked Questions (FAQs)
Q1: What specific chemical compounds does the ’833 patent protect?
A: The patent claims a class of compounds with a core structure defined by a chemical formula, with various substituents as described in the claims. Exact structures are detailed in the patent's specification.
Q2: Are the claims of ’833 patent limited to particular therapeutic uses?
A: The patent may include use claims covering methods of treating specific conditions, but primary claims focus on the chemical compounds and synthesis methods.
Q3: Has the patent been challenged or litigated?
A: There are no public records indicating significant litigation, but patent validity could have been challenged during prosecution or in post-grant proceedings.
Q4: What is the relevance of the patent landscape for current drug development?
A: It informs innovators of potential patent infringement risks or opportunities for licensing, especially as the patent nears or has passed its expiration date.
Q5: How does patent expiration affect commercial opportunities?
A: Post-expiration, generic manufacturers can enter the market, typically leading to price declines and increased competition.
References
[1] U.S. Patent 5,403,833. "Chemical compounds and methods of preparation and use," issued March 28, 1995.
[2] Patent tracking databases (USPTO), available at USPTO.gov.
[3] Relevant scientific literature and prior art cited in patent prosecution.
[4] FDA approvals and regulatory filings relating to the patent's core compounds.
This analysis provides a thorough understanding of the ’833 patent's scope, claims, and position within the patent landscape, essential for strategic decision-making in pharmaceutical development and intellectual property management.
